Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.

To elucidate the mechanisms underlying relapse from chemotherapy in multiple myeloma, we performed a longitudinal study of 33 patients entered into Total Therapy protocols investigating them using gene expression profiling, high-resolution copy number arrays, and whole-exome sequencing. The study illustrates the mechanistic importance of acquired mutations in known myeloma driver genes and the critical nature of biallelic inactivation events affecting tumor suppressor genes, especially TP53, the end result being resistance to apoptosis and increased proliferation rates, which drive relapse by Darwinian-type clonal evolution. The number of copy number aberration changes and biallelic inactivation of tumor suppressor genes was increased in GEP70 high risk, consistent with genomic instability being a key feature of high risk. In conclusion, the study highlights the impact of acquired genetic events, which enhance the evolutionary fitness level of myeloma-propagating cells to survive multiagent chemotherapy and to result in relapse.

[1]  Shankar Vembu,et al.  PhyloWGS: Reconstructing subclonal composition and evolution from whole-genome sequencing of tumors , 2015, Genome Biology.

[2]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[3]  Gábor E. Tusnády,et al.  A comprehensive survey of the mutagenic impact of common cancer cytotoxics , 2016, Genome Biology.

[4]  B. Barlogie,et al.  The Clinical Value of Molecular Subtyping Multiple Myeloma Using Gene Expression Profiling , 2015, Leukemia.

[5]  Julian Gehring,et al.  SomaticSignatures: inferring mutational signatures from single-nucleotide variants , 2014, bioRxiv.

[6]  C. Bastard,et al.  Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.

[7]  D. Hose,et al.  Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma , 2016, Haematologica.

[8]  K. Stamatopoulos,et al.  Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. , 2016, Blood.

[9]  Hong Chang,et al.  Analysis of PTEN deletions and mutations in multiple myeloma. , 2006, Leukemia research.

[10]  T. Chevassut,et al.  The Genetic Architecture of Multiple Myeloma , 2014, Advances in hematology.

[11]  G. Morgan,et al.  Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients , 2014, Blood Cancer Journal.

[12]  B. Barlogie,et al.  Curing myeloma at last: defining criteria and providing the evidence. , 2014, Blood.

[13]  G. Parmigiani,et al.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.

[14]  Philip M Kluin,et al.  Double-hit B-cell lymphomas. , 2011, Blood.

[15]  Xiaoyu Chen,et al.  Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications , 2016, Bioinform..

[16]  A. McKenna,et al.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.

[17]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[18]  L. Bullinger,et al.  Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M3P) , 2015, Annals of Hematology.

[19]  S. Carr,et al.  Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.

[20]  Stein Aerts,et al.  Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia , 2012, Nature Genetics.

[21]  J. Carpten,et al.  Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.

[22]  Winnie S. Liang,et al.  Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease , 2013, British journal of haematology.

[23]  Lisa J. Murray,et al.  Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms , 2013, Leukemia.

[24]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[25]  L. Bullinger,et al.  Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in ‐17p high risk disease , 2015, British journal of haematology.

[26]  Gordon Cook,et al.  Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  N. Schultz,et al.  Deletions linked to TP53 loss drive cancer through p53-independent mechanisms , 2016, Nature.

[28]  Gordon Cook,et al.  APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma , 2014, Nature Communications.

[29]  C. Curtis,et al.  A Big Bang model of human colorectal tumor growth , 2015, Nature Genetics.

[30]  Benjamin J. Raphael,et al.  Pan-Cancer Network Analysis Identifies Combinations of Rare Somatic Mutations across Pathways and Protein Complexes , 2014, Nature Genetics.

[31]  A. Look,et al.  Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. , 2012, Blood.

[32]  M. Weitzman,et al.  APOBEC3 proteins and genomic stability , 2012, Cell cycle.